Martin Tremblay, Ph.D.

As vice president of medicinal chemistry, Martin Tremblay leads a team of passionate and adventurous medicinal chemists who discovered FOG-001, the company’s first-in-class direct TCF-blocking β-catenin inhibitor. 

Prior to joining FogPharma, Martin was senior director of small molecule discovery at Tesaro – A GSK company, where he led several external drug discovery collaborations and contributed to search and evaluation of strategic partnerships. Before that, Martin held positions of increasing responsibility at Infinity Pharmaceuticals, where he ultimately served as the senior director of medicinal chemistry. There, he has been an intellectual and organizational leader for the discovery and early CMC development of three drug candidates, most notably PI3K-g selective inhibitor IPI-549 (eganelisib) and smoothened antagonist IPI-926 (patidegib). 

Martin started his pharmaceutical career as a discovery chemist at Eisai Co. He is an author of over 30 peer-reviewed publications and co-inventor of over 40 patents. 

Martin holds a B.S. biochemistry from Laval University, a Ph.D. in physiology-endocrinology (medicinal chemistry) from Laval University and was a postdoctoral fellow in chemistry at the Scripps Research Institute.